12:00 AM
 | 
Nov 12, 2001
 |  BC Week In Review  |  Company News  |  Deals

Afferon, Icos deal

ICOS exclusively licensed from Afferon worldwide rights to RTX resiniferatoxin to treat urological disorders. ICOS will pay Afferon...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >